



## **Mindset Pharma to Participate in Wonderland: Miami on November 8-9, 2021**

**Toronto, Ontario-- October 26, 2021 - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company")**, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in Microdose's Wonderland: Miami to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 8-9, 2021.

James Lanthier, CEO of Mindset, and Joseph Araujo, CSO of Mindset will give a presentation titled *Beyond Psilocybin: New Frontiers in Psychedelic Drug Design* on Monday, November 8<sup>th</sup> at 12:45 p.m. ET. Register to attend [here](#).

For more information about the event, or to schedule a one-on-one meeting with Mindset's management team, please contact KCSA Strategic Communications at [MindSet@kcsa.com](mailto:MindSet@kcsa.com).

### **About Mindset Pharma**

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at [www.mindsetpharma.com](http://www.mindsetpharma.com).

### **For more information, please contact:**

#### **Investor Contact:**

Allison Soss/Tim Regan  
KCSA Strategic Communications  
Email: [MindSet@kcsa.com](mailto:MindSet@kcsa.com)  
Phone: 212-896-1267/ 347-487-6788

#### **Company Contact:**

James Lanthier, CEO  
Email: [jlanthier@mindsetpharma.com](mailto:jlanthier@mindsetpharma.com)

Jason Atkinson, VP, Corporate Development  
Email: [jatkinson@mindsetpharma.com](mailto:jatkinson@mindsetpharma.com)  
Phone: 416-479-4094

### **Forward-Looking Information**

This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.